Carbohydrate Antigen 242 (CA242)/ Cancer Antigen 724 (CA724)

Carbohydrate antigen 242 (CA242) is a salivary acidified mucin-type glycan antigen with an antigenic determinant cluster of glycan structures that appears on the mucin surface. The presence of glycan antigens as serological tumor markers is significantly elevated from the tumor level and correlates mainly with the development of pancreatic and colon cancer.

Cancer antigen724 (CA724) is one of the laboratory markers for detecting gastric cancer and various digestive tract cancers, which is also a non-specific tumor marker. CA724 is a mucin-like, high molecular weight glycoprotein recognized by the two monoclonal antibodies of cc49 and B72.3, with a molecular weight of 220-400 KD, which is abnormally elevated in various digestive tract tumors and ovarian cancer can be produced. The specificity of the test is high for gastric cancer.

KMD Bioscience, as a manufacturer of in vitro diagnostic reagents, provides raw materials such as antibodies, antigens, enzymes and nanomaterials for in vitro diagnostics. KMD Bioscience has several mature technology platforms, including immunochromatography, latex turbidimetry, chemiluminescence and molecular diagnostics. Our main products are in vitro diagnostic antigens (natural antigens, genetically engineered recombinant antigens), antibodies (monoclonal antibodies, polyantibodies), fluorescent microspheres, etc., which cover a wide range of fields such as cardiovascular, renal, hormonal, diabetes, infectious diseases, autoimmune diseases and so on.

The inventory of reagents associated with glycan antigen 242 (CA242) and gastric cancer antigen 724 (CA724) that KMD Bioscience can offer:

Principle of Cancer Glycoside Antigen

Cancer Antigen is a glycoprotein that is abundantly expressed on the surface of cancer cells or in body fluids. Glycoantigens play an important role in the development and progression of cancer by participating in processes such as cell recognition, adhesion and signaling. It has been found that cancer cells have significant differences in glycosylation modifications compared to normal cells, and this difference leads to an increase in glycan antigens on the surface of cancer cells. Therefore, glycan antigens have become important markers and therapeutic targets for cancer.

The production of glycan antigens is closely related to the activity of glycosyltransferases. Glycosyltransferases are a class of enzymes involved in glycosylation modification, which are capable of transferring sugar groups to specific sites in proteins or lipids, resulting in the formation of glycan antigens. The activity and selectivity of glycosyltransferases determine the type and expression level of glycan antigens. It has been found that the expression of certain glycosyltransferases is abnormally enhanced in cancer cells, leading to overexpression of specific glycan antigens.

Functions of Glycoantigens

In addition to serving as markers, glycan antigens are involved in the adhesion and metastatic processes of tumor cells. It has been found that the glycan antigens on the surface of cancer cells are able to bind to receptors on the surface of surrounding tissues or organs, thus promoting the adhesion and infiltration of cancer cells. This adhesion and infiltration is an important step in cancer metastasis.

Glycoantigens are also involved in signaling processes in tumor cells. Binding of glycan antigens can activate intracellular signaling pathways, thereby affecting life activities such as cell proliferation, differentiation, and modulation. It has been found that overexpression of certain glycan antigens is closely related to the malignant proliferation and anti-regulatory ability of cancer cells. Glycoantigens play an important role in the diagnosis and treatment of cancer. Currently, the detection of glycan antigen levels can assist in the early diagnosis of cancer, the monitoring of disease progression, and the evaluation of treatment effects. Glycoantigens are also widely used in targeted therapy for tumor treatment. By designing antibodies or vaccines against glycan antigens, cancer cells can be selectively recognized and destroyed for therapeutic purposes.

To summarize, the expression of cancer glycan antigens is closely related to the characteristics of cancer cells, and it plays an important role in the occurrence, development and treatment of cancer. Early diagnosis and therapeutic monitoring of cancer can be realized by detecting the levels of glycan antigens. Individualized cancer treatment can be achieved by designing targeted therapeutic drugs against glycan antigens. In the future, research on glycan antigens will continue to deepen, providing more strategies and tools for cancer prevention and treatment.

KMD Bioscience has an excellent in vitro diagnostic reagent development platform, all raw materials have been repeatedly verified through multiple application platforms and a large number of clinical samples, and under strict production process control, we can provide high-quality raw materials to our IVD customers in a sustainable and stable manner. Most of our antigenic raw materials are prepared using mammalian expression systems, with structures and activities closer to natural antigens. Each antigen is produced through rigorous program design and strict performance evaluation, and has excellent stability and specificity. Moreover, our antigenic raw materials can be used in the development of standards, calibrators, quality control products and as immunogens.